Appointments at the Communications Department of the sanofi-aventis Group

Appointments at the Communications Department of the sanofi-aventis Group Paris, September 22, 2004 The sanofi-aventis Group announced today the appointments within the Communications department of the Group, which is headed by Nicole CRANOIS, Senior Vice President, Communications. - Jocelyne COUPAT, Vice President, International Relations - Agnès GARCIA-GIBOT, Vice President, Internal Communications and Corporate Image - Michel JOLY, Vice President, Product PR - William BRATTON, Deputy Vice President, Product PR - Jean-Marc PODVIN, Vice President, Media Relations - Robert SEBBAG, Vice President, Solidarity mission on access to medicine Are also members of the Communications Management Committee: - Xavier LEGRAND DU LAURENS, Vice President, Communications France - Miriam HENN, Vice President, Communications Germany - Charles F. ROUSE, Vice President, Communications USA. The sanofi-aventis Group is the world's 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, vaccines. The sanofi-aventis Group is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY). Important Information In connection with its acquisition of Aventis, Sanofi-Aventis has announced that it is studying the feasibility of merging Aventis with and into Sanofi-Aventis, with Sanofi-Aventis continuing as the surviving corporation. In connection with any merger of Aventis into Sanofi-Aventis, Sanofi-Aventis will file a post-effective amendment to its registration statement on Form F-4 (File no. 333-112314), which will include a prospectus relating to the merger, and will file additional documents with the SEC. Investors are urged to read the registration statement, including any preliminary prospectus or definitive prospectus (when available) relating to the merger, and any other relevant documents filed with the SEC, including all amendments and supplements, because they will contain important information. Free copies of the registration statement, as well as other relevant documents filed with the SEC, may be obtained at the SEC's web site at www.sec.gov. At the appropriate time, Sanofi-Aventis will provide investors with information on how to obtain any merger-related documents for free from Sanofi-Aventis or from its duly appointed agents. ------------------------------------------------------------ Informasjonen er sendt gjennom Waymaker http://www.waymaker.no